Immunopharmacology |
||||||
Friday, 12 April 2002 |
||||||
Organizer |
K. Mašek (Prague, Czech Republic) J.W. Hadden (Tampa, USA) |
|||||
Immunopharmacology of life-threatening diseases: insight into the new millennium |
||||||
Session I |
Abstract no
|
|||||
| Chair | K. Mašek (Prague, Czech Republic) J.W. Hadden (Tampa, USA) |
|||||
| 9.30 – 9.55 |
New approaches in the treatment of some viral diseases: the antiviral compound with immuno-modulatory property K. Mašek (Prague, Czech Republic) |
|||||
| 9.55 – 10.20 |
Effective immunotherapy of head and neck cancer J.W. Hadden (Tampa, USA) |
|||||
| 10.20 – 10.45 |
Preventive and curative vaccination strategies F. Audibert (Paris, France) |
|||||
| 10.45 – 11.15 | coffee break | |||||
| 11.15 – 11.40 |
Can immunomodulators play a role in preventive and therapeutic measures against infectious biological syndrome K.N. Masihi (Berlin, Germany) |
|||||
| 11.40 – 11.55 |
Hyperbaric Oxygen Therapy for chronic systemic infections in Chronic Fatigue Syndrome E. Van Hoof, D. Coomans, P. De Becker, K. De Meirleir, and R. Cluydts (Brussels, Belgium / Australia) |
92
|
||||
| 11.55 – 12.10 |
Hepatocytes growth factor is a marker of liver injury in chronic hepatitis C K. Zwirska-Korczala, A.P. Dziambor, A. Wiczkowski, A. Berdowska, A. Sitkiewicz, and M. Kukla (Zabrze, Poland) |
93
|
||||
| 12.10 – 12.25 |
APO-1/Fas and bcl-2 serum concentration in myasthenia gravis patients D. Czyzewski, J. Wojtacha, K. Zwirska-Korczala, and J. Dobosz (Zabrze, Poland) |
94
|
||||
| 12.30 | discussion | |||||
| 12.30 | end of workshop 9 | |||||
